Lactic acid

The smallest 3-carbon alpha-hydroxy acid (AHA) and a component of the skin’s endogenous natural moisturizing factor (NMF). In topical dermatology, lactic acid occupies a distinctive niche: it functions as both a chemical exfoliant (via corneocyte-desquamation, the AHA class mechanism shared with glycolic-acid) and a humectant (via hygroscopic lactate binding water in the stratum corneum). This dual function makes it a better-tolerated alternative to glycolic acid for dry or barrier-impaired skin, particularly for photoaging management and maintenance exfoliation. At medical-grade peel concentrations (30–50%), it also stimulates a collagen-producing wound response comparable to other medium-depth AHA peels.

Lactic acid is simultaneously an endogenous metabolite (the terminal product of anaerobic glycolysis, circulating in blood and incorporated into skin NMF) and an exogenous topical — a rare situation that shapes its tolerability profile and largely eliminates systemic toxicity concerns at cosmetic doses.

Poly-L-lactic acid (PLLA), marketed as Sculptra, is a distinct product: a biodegradable injectable biostimulator that slowly hydrolyzes to L-lactic acid in the dermis, triggering a sustained collagen-stimulating wound response. Its mechanism and clinical use are categorically different from topical lactic acid and are covered briefly in the PLLA Fillers section below.

Identity

PubChem CID: 612 (DL-lactic acid, racemic; the form most common in cosmetics); CID 107689 (L-lactic acid, the biologically-active stereoisomer and endogenous NMF component)
InChIKey (DL): JVTAAEKCZFNVCJ-UHFFFAOYSA-N
CAS (DL): 50-21-5; CAS (L-lactic): 79-33-4
ChEMBL: CHEMBL1200559 (DL); CHEMBL330546 (L-form)
DrugBank: DB04398 (DL); DB14475 (L-form)
Molecular formula: C₃H₆O₃
Molecular weight: 90.08 Da (the smallest AHA after glycolic acid at 76.05 Da)
Canonical SMILES: CC(C(=O)O)O
LogP (XLogP3): −0.7 (hydrophilic; poor membrane penetration at neutral pH)
Topological polar surface area: 57.5 Å²
Hydrogen bond donors / acceptors: 2 / 3
Chiral centers: 1 (C-2; undefined in racemic DL form)
Class: α-hydroxy acid (AHA); the α-hydroxy and carboxylic acid groups on the same 3-carbon backbone define the class

Stereoisomers and formulation notes

Three stereochemical forms exist in commercial and biological contexts:

Form	CID	CAS	Biological role	Commercial use
L-lactic acid	107689	79-33-4	Endogenous; NMF component; lactate-pyruvate cycle	Some “high-purity” cosmetics; PLLA filler hydrolysate
D-lactic acid	5460041	10326-41-7	Minor; bacterial fermentation product	Rare; not used therapeutically
DL-lactic acid (racemic)	612	50-21-5	Not endogenous	Most cosmetic and peel products

Biological activity differences between L- and DL-lactic acid in topical application are subtle and not clearly established in RCT data — formulations typically do not report stereochemical purity, and existing clinical trials used unspecified or racemic preparations. For AHA-class exfoliation, the activity is believed to be stereochemistry-independent (both L and D forms disrupt corneocyte ionic cohesion). NMF-mimicry by endogenous lactate is specific to the L-form, but quantitative contribution of exogenous D-lactic acid to NMF is not studied. needs-replication

Mechanism of action

Primary: AHA corneocyte desquamation

AHAs in their protonated (low-pH) form penetrate into the lower stratum corneum and chelate calcium ions from the calcium-sensitive desmoglein and desmocollin junctional adhesion complexes between corneocytes. Reduced ionic cohesion loosens intercellular attachments, accelerating normal corneocyte shedding from the skin surface. The downstream effects at cosmetic concentrations (5–15%, pH ~3.5–4.5) are:

Thinned, more translucent stratum corneum
Improved surface texture and smoothness
Reduced hyperkeratosis in photodamaged skin
Normalization of disordered corneocyte maturation (common in actinic-damaged epidermis)

At higher concentrations (≥20%, medical peel range) and lower pH (<3.5), the progressive disruption of epidermal tight junctions triggers a controlled wound response with transient inflammation, keratinocyte proliferation, and secondary dermal remodeling including procollagen upregulation ¹. The keratinocyte wound-response mechanism overlaps with glycolic acid’s mechanism at equivalent concentrations; lactic acid’s larger molecular weight (90.08 vs 76.05 Da) limits penetration rate per unit concentration, making equivalent exfoliation effect achievable at slightly higher concentrations or lower tolerability burden.

Secondary: NMF humectancy and barrier support

Lactate is a constituent of the natural moisturizing factor (NMF) — the hygroscopic mixture of amino acids, organic acids, and salts in the stratum corneum’s corneocyte cytoplasm that maintains water content. Endogenous NMF lactate concentration in the upper stratum corneum of healthy adults is approximately 5–10% of total NMF by weight (exact proportion varies by skin site, age, and hydration state; dose-response-unclear). Exogenous topical lactic acid augments this pool by two mechanisms: (1) direct penetration of undissociated lactic acid (pKa 3.86) into the stratum corneum, where it becomes part of the hygroscopic NMF reservoir; (2) pH buffering — topical lactic acid shifts the stratum corneum surface pH toward its optimal acidic range (~4.5–5.5), which activates endogenous serine proteases (KLK5, KLK7) that mediate physiological desquamation and also supports ceramide-synthetic enzymes (beta-glucocerebrosidase, acidic sphingomyelinase) that generate barrier lipids ².

This humectancy mechanism differentiates lactic acid from glycolic acid: lactic acid is a better humectant and more useful in dry, barrier-impaired skin. Glycolic acid at equivalent pH lacks a comparable endogenous-component identity in NMF and is primarily a desquamating agent.

Lactic acid vs glycolic acid: key distinctions

Property	Lactic acid	Glycolic acid
Molecular weight	90.08 Da	76.05 Da
pKa	3.86	3.83
Penetration rate (topical)	Slower (larger MW)	Faster (smallest AHA)
Humectancy	Strong (NMF component)	Minimal
Tolerability	Better; preferred for sensitive/dry skin	More irritating at equivalent concentration
Equivalent exfoliation concentration	~12% LA ≈ 8% GA for mild photoaging	Reference
NMF-mimicry	Yes (L-lactic = endogenous)	No
Cost	Low	Low
Data quality	Strong (Stiller 1996 RCT)	Strong (Stiller 1996 RCT; Smith 1996 comparative study for concentration-response)

At matched pH and matched free-acid bioavailability (the variable that drives AHA-class activity), lactic and glycolic acids produce comparable exfoliation outcomes — the primary clinical differences are tolerability and humectancy rather than categorical efficacy differences ³.

Clinical evidence — topical use

Foundational RCT: Stiller et al. 1996

The most-cited comparative evidence for topical lactic acid in photoaging is a 22-week double-blind, vehicle-controlled RCT by Stiller et al. ³. Seventy-four women aged 40–70 with moderately severe photodamaged skin applied 8% glycolic acid, 8% L-lactic acid, or vehicle twice daily to face and forearms.

Key results:

Physician-graded improvement in ≥1 severity grade: 76% (glycolic acid), 71% (lactic acid), 40% (vehicle); both active arms statistically superior to vehicle (p<0.05)
Both AHAs improved mottled hyperpigmentation, roughness, and fine wrinkling compared to vehicle
No statistically significant difference between 8% glycolic acid and 8% L-lactic acid on any efficacy endpoint
Tolerability similar across arms; neither AHA produced significantly higher irritation than vehicle at 8%

This study established that lactic acid and glycolic acid are clinically equivalent at matched concentration and pH for mild-moderate photoaging, while positioning lactic acid as the preferred option when humectancy or dry-skin tolerability is a priority.

Smith 1996: dose-response (5% vs 12% lactic acid)

Smith 1996 ¹ examined epidermal and dermal responses to 5% versus 12% lactic acid twice daily for 3 months in a non-randomized comparative study. At 12%: significant improvements in epidermal and dermal firmness and thickness; improved texture and wrinkle appearance. At 5%: surface and epidermal benefits only, with no dermal signal. This study established the concentration-response relationship for lactic acid topical use — cosmetic-range concentrations (5%) produce surface-layer effects, while higher concentrations (12%+) are required for dermal-level remodeling. needs-replication (non-randomized design; n not reported)

Recent studies (2019–2026 recency search)

Almeman 2024 ⁴: comprehensive clinical and legal review of AHAs in dermatological practice (Clinical, Cosmetic and Investigational Dermatology; gold OA; 27 citations at time of archiving; FWCI 32 — 100th citation percentile). Confirms the AHA class evidence base: corneocyte-desquamation mechanism is well-established; clinical evidence strongest for photoaging, acne, and hyperpigmentation; regulatory considerations (EU cosmetics directive restricts AHA concentrations above 10% for cosmetics) reviewed.

Singh & Chauhan 2024 ⁵: prospective comparative study of lactic acid 30% + ferulic peel 12% vs TCA 10% + ferulic peel 12% for photoaging skin (Aesthetic Plastic Surgery; n not reported in DOI lookup; abstract-only). Lactic acid-containing combination peel produced comparable photoaging improvement to TCA combination with favorable tolerability profile. needs-replication

Fanning & Ibrahim 2023 ⁶: retrospective case series treating mild-to-moderate facial aging with a combination peel containing 6% TCA + 12% lactic acid (Journal of Cosmetic Dermatology; 3 citations). Documents clinical utility of lactic acid as a peel acidifier/carrier in combination formulations.

Razi & Rao 2022 ⁷: in-vivo reflectance confocal microscopy and Vivascope visualization of facial peeling mechanisms including lactic acid peels (Dermatologic Therapy; 7 citations). Provides mechanistic imaging support for the corneocyte-desquamation mechanism and documents in-vivo collagen response to peel concentrations.

Fluhr 2025 (barrier/NMF) ²: mechanistic review of emollients for xerosis and skin barrier function, contextualizing lactate’s role as an NMF component and hygroscopic agent in stratum corneum hydration (International Journal of Dermatology; 17 citations; FWCI 148 — exceptional citation velocity for a recent paper). Independently supports the NMF-humectancy mechanism of lactic acid.

Note on R25 recency search results: No meta-analyses or large RCTs (n>100) specifically evaluating topical lactic acid for photoaging were identified in the 2019–2026 window. The evidence base for this compound is dominated by older RCTs (Stiller 1996, Smith 1996) that remain unreplicated at equivalent power. Recent evidence is primarily reviews, combination-peel case series, and mechanistic studies. This is an expected pattern for an established cosmeceutical ingredient where further industry-funded RCTs are unlikely (market presence is not contingent on new trial data).

PLLA fillers (Sculptra) — injectable biostimulator

Poly-L-lactic acid (PLLA) is a biodegradable injectable filler consisting of polylactic acid microspheres (50–80 µm diameter) suspended in sterile water and carboxymethylcellulose. Trade name: Sculptra (Galderma). Related product: Sculptra Aesthetic.

FDA approval history:

August 2004: FDA-approved for HIV-associated facial lipoatrophy (hollow, sunken cheeks from lipodystrophy due to antiretroviral therapy)
July 2009: FDA-approved for cosmetic use (correction of shallow-to-deep nasolabial fold wrinkles in immunocompetent patients)
Broad off-label use for facial volumization, skin laxity, and body contouring has expanded substantially

Mechanism: Injected PLLA microspheres are not immediately biologically active. The inflammatory foreign-body response to the microspheres drives recruitment of fibroblasts and macrophages; as PLLA hydrolyzes slowly (~24 months for full absorption), the sustained stimulation produces progressive neocollagenesis (type I and III collagen deposition). This is categorically a wound-healing and collagen-biostimulation mechanism, distinct from the topical AHA-corneocyte-desquamation mechanism of lactic acid solutions. Key evidence: Goldberg 2020 ⁸ (stimulation of collagenesis by PLLA-containing absorbable suture and injectable, documenting parallel sustained collagen synthesis); Kim & Ryoo 2023 ⁹ (PLLA effects on adipogenesis and collagen gene expression in adipocytes irradiated with UVB — in vitro mechanistic study documenting PLLA increases collagen I/III mRNA and suppresses adipogenesis, suggesting PLLA may counter both volume deflation and UV-accelerated ECM degradation).

Clinical use: Sculptra effect is gradual (clinical improvement over 3–6 months post-injection), long-lasting (~2 years), and technique-dependent. Key complications: papule formation (subcutaneous nodules from PLLA aggregation) if improperly diluted or injected superficially; requires experienced injector. See dermatologic-resurfacing for class-level context. needs-canonical-id — no dedicated PLLA compound page exists; this section is the current canonical home.

Pharmacokinetics (topical)

Topical lactic acid pharmacokinetics are pH-dependent and concentration-dependent:

Penetration: Only the undissociated acid (pKa 3.86) crosses the lipid-rich stratum corneum. At formulation pH 3.5, ~70% of lactic acid is undissociated; at pH 5.0, only ~7%. This drives the critical formulation principle: for AHA activity, pH must be kept low (typically 3.0–4.5 for cosmetics, 1.8–3.5 for peels).
Systemic absorption: Minimal at cosmetic concentrations — topical lactic acid contributes negligibly to circulating lactate (which is produced in gram quantities daily by anaerobic glycolysis). This is a practical safety advantage.
Neutralization: Professional peels are neutralized with bicarbonate or water; at-home products are self-neutralized by the buffering capacity of the skin surface and natural secretions.
Skin penetration depth vs concentration: Cosmetic 5–12% penetrates into upper stratum corneum; medical-grade 30–70% penetrates to granular layer and variable dermal depth.

Tolerability, safety, and combinations

Pregnancy safety: Topical lactic acid at cosmetic concentrations (≤12%) is generally regarded as safe in pregnancy — it is an endogenous metabolite with negligible systemic absorption at topical doses. This contrasts with retinoids (category D/X) and salicylic acid at high concentrations. Lactic acid is often the preferred exfoliant for pregnant patients seeking mild photoaging support.

Irritancy: Lower than glycolic acid at matched concentration due to larger molecular size (slower penetration) and humectant counterbalancing of barrier disruption. Typical side effects at 8–12%: transient stinging, mild erythema in the first 2–4 weeks of use. At peel concentrations (30–50%): erythema, peeling, post-inflammatory hyperpigmentation risk (particularly in Fitzpatrick III–VI skin types).

Combination use:

+ niacinamide + glycerin (barrier-repair triad): lactic acid provides exfoliation while niacinamide upregulates ceramide synthesis and glycerin augments hygroscopic moisture retention — addresses AHA-induced barrier perturbation
+ retinoids (tretinoin/retinol): typically alternating-day or morning/evening split to avoid additive irritation; complementary mechanisms (retinoids via RAR-mediated collagen synthesis; lactic acid via desquamation/barrier support)
+ ascorbic-acid: morning (ascorbic acid, oxidation-sensitive) + evening (lactic acid, pH-sensitive) split; complementary antioxidant/collagen-cofactor + exfoliation mechanisms
+ salicylic-acid (beta-hydroxy acid): lactic acid is water-soluble (targets keratinocyte surface adhesion), SA is oil-soluble (penetrates follicular orifices); useful in acne-prone photodamaged skin

Contraindications: Active eczema, rosacea, or other inflammatory dermatoses at the application site (lactic acid will worsen barrier compromise). Avoid in combination with strong retinoids on same day at high concentrations.

Effects on aging hallmarks

Hallmark	Effect	Evidence
loss-of-proteostasis	Restores normal corneocyte turnover kinetics in photodamaged epidermis; reduces pathological retention of dysfunctional surface corneocytes; augments NMF lactate pool	³, ¹
chronic-inflammation	Indirect at cosmetic doses: improved barrier reduces inflammatory signaling from perturbed epidermis; at high peel concentrations: transiently pro-inflammatory (wound-response mediated)	⁴

Classification

AHA class: alpha-hydroxy acid (AHA); 3-carbon; second-smallest AHA
Intervention class: AHA-corneocyte-desquamation + NMF-humectancy — see intervention-classes
Skin-aging phenotype targets: skin-aging — photoaging, rough texture, uneven pigmentation, fine wrinkles; xerosis/dry skin; barrier dysfunction
SENS strategy: No direct SENS-category mapping for topical exfoliation; PLLA collagen-biostimulation is distantly analogous to ECM-repair strategies

Limitations and gaps

No large post-2000 RCT for topical lactic acid as monotherapy in photoaging. The evidence base rests on Stiller 1996 (n=74) and Smith 1996 (concentration-response). Neither has been independently replicated in a large randomized trial. Industry incentives to fund new RCTs are low as lactic acid is off-patent. needs-replication
Stereochemistry poorly characterized in trials. No major trial has used L-lactic acid exclusively and compared it to racemic DL-lactic acid for NMF or exfoliation efficacy. needs-replication
Long-term daily-use safety in elderly populations unknown. Short-term tolerability data exists; no study has examined whether decades of lactic acid use modifies skin barrier biology or exfoliation enzyme regulation. long-term-unknown
PLLA injection mechanism is better-evidenced for volume restoration than for anti-aging biomarker endpoints. Collagen stimulation is documented histologically but no RCT has used epigenetic clock or dermal proteostasis biomarkers as endpoints for PLLA fillers. no-mechanism
Dose-response curve for humectancy contribution is poorly quantified. Optimal concentration and frequency for NMF augmentation vs exfoliation have not been formally optimized in a factorial design. dose-response-unclear
glycolic-acid compound page does not exist yet — implicit stub; the head-to-head comparison on this page requires a corresponding glycolic-acid page for full cross-referencing.

Footnotes

doi:10.1016/s0190-9622(96)90602-7 · Smith WP · J Am Acad Dermatol 1996;35(3 Pt 1):388–391 · comparative study (non-randomized; abstract describes no randomization or control arm) · n not reported in abstract or DOI lookup · 5% vs 12% lactic acid twice daily × 3 months · 12% produced increased epidermal and dermal firmness and thickness and clinical improvement in smoothness and lines/wrinkles; 5% produced surface and epidermal changes only, no dermal signal · model: human (in vivo); 109 citations in archive; no-fulltext-access (closed access, no local PDF) ↩ ↩² ↩³
doi:10.1111/ijd.17790 · Fluhr JW et al. · Int J Dermatol 2025 · review (mechanistic) · emollients for xerosis and skin barrier function; contextualizes NMF lactate biology and hygroscopic function; 17 citations; FWCI 148.2 (exceptional recent citation velocity); bronze OA ↩ ↩²
doi:10.1001/archderm.1996.03890300047009 · Stiller MJ, Bartolone J, Stern R, Smith S, Kollias N, Gillies R, Drake LA · Arch Dermatol 1996;132(6):631–636 · n=74 (women 40–70 yr, moderate photodamage) · rct · double-blind vehicle-controlled 22-week trial · 8% glycolic acid vs 8% L-lactic acid vs vehicle twice daily to face and forearms · physician-graded ≥1-grade improvement: 76% GA, 71% LA, 40% vehicle (p<0.05 for both active vs vehicle); no significant GA vs LA difference on any endpoint · model: human (in vivo); 101 citations in archive ↩ ↩² ↩³
doi:10.2147/CCID.S453243 · Almeman AA · Clin Cosmet Investig Dermatol 2024 · review (comprehensive clinical + legal) · gold OA; local PDF at a local paper archive · covers AHA class mechanism, clinical evidence, and EU/US regulatory framework; 27 citations; FWCI 32.0 (100th citation percentile) ↩ ↩²
doi:10.1007/s00266-024-04136-5 · Singh S, Chauhan A · Aesthetic Plast Surg 2024 · comparative study · lactic acid 30% + ferulic 12% vs TCA 10% + ferulic 12% for photoaging · abstract-only; no-fulltext-access ↩
doi:10.1111/jocd.15814 · Fanning J, Ibrahim O · J Cosmet Dermatol 2023 · retrospective case series · 6% TCA + 12% lactic acid combination peel for mild-to-moderate facial aging · hybrid OA; 3 citations ↩
doi:10.1111/dth.15846 · Razi S, Rao B · Dermatol Ther 2022 · in-vivo reflectance confocal microscopy study · visualization of peeling mechanism including lactic acid concentration effects; 7 citations; hybrid OA ↩
doi:10.1111/jocd.13371 · Goldberg DJ et al. · J Cosmet Dermatol 2020 · in-vivo + histology · PLLA-containing absorbable suspension suture and injectable: collagenesis stimulation with parallel sustained clinical benefit; 24 citations; FWCI 2.7 ↩
doi:10.5021/ad.22.177 · Kim HW, Ryoo YW · Ann Dermatol 2023 · in-vitro · PLLA effects on adipogenesis and collagen gene expression in adipocytes irradiated with UVB; 8 citations; FWCI 4.0; diamond OA; download pending ↩

🧬 Aging Wiki

Explorer

lactic-acid